Yu Sunakawa
About
Yu Sunakawa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Yu Sunakawa has authored 183 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 141 papers in Oncology, 100 papers in Pulmonary and Respiratory Medicine and 47 papers in Cancer Research. Recurrent topics in Yu Sunakawa's work include Colorectal Cancer Treatments and Studies (98 papers), Gastric Cancer Management and Outcomes (62 papers) and Lung Cancer Treatments and Mutations (40 papers). Yu Sunakawa is often cited by papers focused on Colorectal Cancer Treatments and Studies (98 papers), Gastric Cancer Management and Outcomes (62 papers) and Lung Cancer Treatments and Mutations (40 papers). Yu Sunakawa collaborates with scholars based in Japan, United States and Germany. Yu Sunakawa's co-authors include Heinz‐Josef Lenz, Sebastian Stintzing, Yasutsuna Sasaki, Wataru Ichikawa, Ken‐ichi Fujita, Dongyun Yang, Kaori Kawara, Takako Eguchi Nakajima, Fumio Nagashima and Yuko Akiyama and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Yu Sunakawa
167 papers receiving 1.8k citations
Peers
Yu Sunakawa
Stephen Welch Canada
Philip J. Gold United States
Bart Jacobs Netherlands
Jieqiong Liu China
Phuong K. Morrow United States
Petra Ruemmele Germany
David Páez Spain
Yan Qin China
Daniel A. Nikcevich United States
Fabienne Thomas France
Citations per year, relative to Yu Sunakawa Yu Sunakawa (= 1×)
peers
Stephen Welch
Countries citing papers authored by Yu Sunakawa
Since
Specialization
Citations
This map shows the geographic impact of Yu Sunakawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Sunakawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Sunakawa more than expected).
Fields of papers citing papers by Yu Sunakawa
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yu Sunakawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Sunakawa. The network helps show where Yu Sunakawa may publish in the future.
Co-authorship network of co-authors of Yu Sunakawa
This figure shows the co-authorship network connecting the top 25 collaborators of Yu Sunakawa. A scholar is included among the top collaborators of Yu Sunakawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Sunakawa. Yu Sunakawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kotani, Daisuke, Hideaki Bando, Hiroya Taniguchi, et al.. (2024). Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703).. Journal of Clinical Oncology. 42(16_suppl). 3585–3585.
2.
Yamamoto, Hiroyuki, Yoshiyuki Watanabe, Hiroyuki Arai, et al.. (2024). Microsatellite instability: A 2024 update. Cancer Science. 115(6). 1738–1748.
3.
Tanizaki, Junko, Koji Matsumoto, Toshiki Masuishi, et al.. (2024). Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).. Journal of Clinical Oncology. 42(16_suppl). 3025–3025.
4.
Kagawa, Yoshinori, Chaochen Wang, Yongzhe Piao, et al.. (2024). Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study. Targeted Oncology. 19(4). 575–585.
5.
Takeda, Hiroyuki, Shigeaki Nishina, Sho Suzuki, et al.. (2024). 486P Genomic profile differences between primary and recurrent tumors in curatively resected gastric cancer: The Liquid-GEAR study. Annals of Oncology. 35. S193–S194.
6.
Arai, Hiroyuki, Takashi Tsuda, Yu Sunakawa, et al.. (2024). Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID ). Cancer Medicine. 13(7). e7107–e7107.
7.
Yasui, Hisateru, Masato Nakamura, Takashi Sagawa, et al.. (2023). Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16. ESMO Open. 8(5). 101636–101636.
8.
Matoba, Ryo, Satoshi Yuki, Manabu Shiozawa, et al.. (2023). The BEETS (JACCRO CC-18) Trial: An Observational and Translational Study of BRAF -Mutated Metastatic Colorectal Cancer. Future Oncology. 19(17). 1165–1174.
9.
Mizukami, Takuro, Hiroyuki Takeda, Yoshiki Horie, et al.. (2021). Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment. Nutrition and Cancer. 74(2). 539–545.
10.
Shigefuku, Ryuta, Tsunamasa Watanabe, Takuro Mizukami, et al.. (2021). Prediction of esophagogastric varices associated with oxaliplatin administration. JGH Open. 5(11). 1289–1297.
11.
Sunakawa, Yu, Kaoru Mogushi, Heinz‐Josef Lenz, et al.. (2018). Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer. Molecular Cancer Therapeutics. 17(12). 2788–2795.
12.
Berger, Martin D., Sebastian Stintzing, Volker Heinemann, et al.. (2017). A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clinical Cancer Research. 24(4). 784–793.
13.
Stremitzer, Stefan, Wu Zhang, Dongyun Yang, et al.. (2016). Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. Molecular Cancer Therapeutics. 15(11). 2814–2821.
14.
Matsusaka, Satoshi, Diana L. Hanna, Shu Cao, et al.. (2016). Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clinical Cancer Research. 22(13). 3218–3226.
15.
Matsusaka, Satoshi, Wu Zhang, Shu Cao, et al.. (2016). TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. Molecular Cancer Therapeutics. 15(6). 1405–1411.
16.
Sunakawa, Yu, Wataru Ichikawa, Akihito Tsuji, et al.. (2016). Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials. Clinical Colorectal Cancer. 16(3). e171–e180.
17.
Stintzing, Sebastian, Wu Zhang, Volker Heinemann, et al.. (2015). Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Molecular Cancer Therapeutics. 14(10). 2374–2381.
18.
Ning, Yan, Diana L. Hanna, Wu Zhang, et al.. (2015). Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Molecular Cancer Therapeutics. 14(10). 2401–2408.
19.
Ning, Yan, Armin Gerger, Wu Zhang, et al.. (2013). Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy. Molecular Cancer Therapeutics. 13(2). 528–539.
20.
Tsuji, Akihito, Masato Nakamura, Yu Sunakawa, et al.. (2013). A Phase II Study of Cetuximab and MFOLFOX6 in MCRC Including Prospective Early Tumor Shrinkage Analysis (JACCRO-CC05). Annals of Oncology. 24. iv94–iv94.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Stephen Welch Breakdown of academic impact, for papers by Philip J. Gold Breakdown of academic impact, for papers by Bart Jacobs Breakdown of academic impact, for papers by Jieqiong Liu Breakdown of academic impact, for papers by Phuong K. Morrow Breakdown of academic impact, for papers by Petra Ruemmele Breakdown of academic impact, for papers by David Páez Breakdown of academic impact, for papers by Yan Qin Breakdown of academic impact, for papers by Daniel A. Nikcevich Breakdown of academic impact, for papers by Fabienne Thomas